Company: DNLI
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001714899-25-000193
Chunk: 424

Company: Denali Therapeutics Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 424
---
320,873 296,653 Personnel related general and administrative expenses22,079 17,643 60,932 53,833 Other general and administrative expenses13,405 7,306 36,172 21,546 Total general and administrative expenses35,484 24,949 97,104 75,379 Segment operating expenses137,434 123,187 417,977 372,032 Segment gain from divestiture of small molecule programs— — — 14,537 Segment loss from operations(137,434)(123,187)(417,977)(357,495)Segment interest and other income, net10,532 15,995 33,986 49,475 Segment loss before income taxes$(126,902)$(107,192)$(383,991)$(308,020)

There is no difference between the segment loss before income taxes and total consolidated loss before income taxes for the three and nine months ended September 30, 2025 and 2024. 

21

ITEM 2.     MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q. This discussion and analysis and other parts of this report contain forward-looking statements based upon current beliefs, plans, and expectations related to future events and our future financial performance that involve risks, uncertainties, and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts, and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the section titled “Risk Factors” included in this Quarterly Report on Form 10-Q.

Forward-looking statements include, but are not limited to, statements about:

•the progress, success, cost, and timing of our development activities, preclinical studies, and clinical trials, and in particular the development of our blood-brain barrier (“BBB”) platform, programs, and biomarkers, including the initiation and completion of studies or trials and related preparatory work, enrollment in such trials, the timing of when data from clinical trials will become available, the advancement of new molecule entities into clinical development and related timing, and the filing of investigational new drug